Analysis and Commentary Lisa Ellington 6/3/22 Analysis and Commentary Lisa Ellington 6/3/22 Q&A about User Fees, Budget Information, and Reconciliation Read More Advocacy at a Glance Lisa Ellington 6/3/22 Advocacy at a Glance Lisa Ellington 6/3/22 Emerging Information on the FY23 Budget Appropriations Process Read More Analysis and Commentary Lisa Ellington 5/27/22 Analysis and Commentary Lisa Ellington 5/27/22 Excerpts from the Alliance’s Testimony to the House Appropriations Committee’s Subcommittee on Agriculture, Rural Development, Food and Drug Administration and Related Agencies. Read More Advocacy at a Glance Lisa Ellington 5/27/22 Advocacy at a Glance Lisa Ellington 5/27/22 Alliance Unveils New Website: www.strengthenfda.org Read More Analysis and Commentary Lisa Ellington 5/20/22 Analysis and Commentary Lisa Ellington 5/20/22 What CBER Director Dr. Marks Said to the Alliance Read More Advocacy at a Glance Lisa Ellington 5/20/22 Advocacy at a Glance Lisa Ellington 5/20/22 Commissioner Califf Testifies on FY23 Priorities; Responses to Infant Formula Shortage Read More Analysis and Commentary Lisa Ellington 5/13/22 Analysis and Commentary Lisa Ellington 5/13/22 What CVM Director Dr. Shuren Said to the Alliance Read More Advocacy at a Glance Lisa Ellington 5/13/22 Advocacy at a Glance Lisa Ellington 5/13/22 Commissioner Califf to Testify Before House Appropriations Committee; FDA Leaders Discussing FY 23 Budget Priorities; the House User Fee Bill Read More Advocacy at a Glance Lisa Ellington 5/6/22 Advocacy at a Glance Lisa Ellington 5/6/22 How FDA Is Funded; User Fee Reauthorization Legislation Released in the House; White House Conference on Hunger, Nutrition, and Health Announced for September Read More Analysis and Commentary Lisa Ellington 5/6/22 Analysis and Commentary Lisa Ellington 5/6/22 Alliance Members Encouraged to Submit Testimony to House Ag/FDA Subcommittee in Support of the Alliance’s FY 23 “Ask” Read More Analysis and Commentary Lisa Ellington 4/29/22 Analysis and Commentary Lisa Ellington 4/29/22 What Dr. Califf Said to the Senate; What CVM Director Dr. Solomon Said to the Alliance Read More Advocacy at a Glance Lisa Ellington 4/29/22 Advocacy at a Glance Lisa Ellington 4/29/22 Commissioner Califf Testifies in Senate; House/Senate Appropriations Leaders Have First Informal Chat About Total Spending for FY 23; Inspections, Budgeting, and the Pandemic Read More Analysis and Commentary STEVEN GROSSMAN 4/22/22 Analysis and Commentary STEVEN GROSSMAN 4/22/22 Q&A: the President’s Budget Request and our Hill visits to advocate for more FDA funding. Read More Advocacy at a Glance STEVEN GROSSMAN 4/22/22 Advocacy at a Glance STEVEN GROSSMAN 4/22/22 Alliance Concludes Second Round of Hill Visits to Request Increased FDA Funding; Tapes/transcripts for past/upcoming Alliance webinars Read More Analysis and Commentary STEVEN GROSSMAN 4/15/22 Analysis and Commentary STEVEN GROSSMAN 4/15/22 Summaries of the Alliance webinars with Associate Commissioner for Regulatory Affairs Judy McMeekin and with CFSAN Director Dr. Susan Mayne Read More Advocacy at a Glance STEVEN GROSSMAN 4/15/22 Advocacy at a Glance STEVEN GROSSMAN 4/15/22 More on President’s request for an FDA BA of $3.653 Billion Total; Volunteers Sought for Hill Meetings April 20/21 and beyond Read More Advocacy at a Glance STEVEN GROSSMAN 4/8/22 Advocacy at a Glance STEVEN GROSSMAN 4/8/22 Alliance Supports Administration Call for $336 Million Increase in FY 23; Encouraging Members of Congress to request increased FDA funding. Read More Analysis and Commentary STEVEN GROSSMAN 4/8/22 Analysis and Commentary STEVEN GROSSMAN 4/8/22 Summary of the Alliance webinar with CDER Director Dr. Patrizia Cavazzoni Read More Analysis and Commentary STEVEN GROSSMAN 4/1/22 Analysis and Commentary STEVEN GROSSMAN 4/1/22 Administration seeks FY23 FDA Increase of $336 Million; New Resources Support Broad Range of FDA Programs. Read More Advocacy at a Glance STEVEN GROSSMAN 4/1/22 Advocacy at a Glance STEVEN GROSSMAN 4/1/22 President’s FY 23 budget request FAQ’s Read More Newer Posts Older Posts
Analysis and Commentary Lisa Ellington 6/3/22 Analysis and Commentary Lisa Ellington 6/3/22 Q&A about User Fees, Budget Information, and Reconciliation Read More
Advocacy at a Glance Lisa Ellington 6/3/22 Advocacy at a Glance Lisa Ellington 6/3/22 Emerging Information on the FY23 Budget Appropriations Process Read More
Analysis and Commentary Lisa Ellington 5/27/22 Analysis and Commentary Lisa Ellington 5/27/22 Excerpts from the Alliance’s Testimony to the House Appropriations Committee’s Subcommittee on Agriculture, Rural Development, Food and Drug Administration and Related Agencies. Read More
Advocacy at a Glance Lisa Ellington 5/27/22 Advocacy at a Glance Lisa Ellington 5/27/22 Alliance Unveils New Website: www.strengthenfda.org Read More
Analysis and Commentary Lisa Ellington 5/20/22 Analysis and Commentary Lisa Ellington 5/20/22 What CBER Director Dr. Marks Said to the Alliance Read More
Advocacy at a Glance Lisa Ellington 5/20/22 Advocacy at a Glance Lisa Ellington 5/20/22 Commissioner Califf Testifies on FY23 Priorities; Responses to Infant Formula Shortage Read More
Analysis and Commentary Lisa Ellington 5/13/22 Analysis and Commentary Lisa Ellington 5/13/22 What CVM Director Dr. Shuren Said to the Alliance Read More
Advocacy at a Glance Lisa Ellington 5/13/22 Advocacy at a Glance Lisa Ellington 5/13/22 Commissioner Califf to Testify Before House Appropriations Committee; FDA Leaders Discussing FY 23 Budget Priorities; the House User Fee Bill Read More
Advocacy at a Glance Lisa Ellington 5/6/22 Advocacy at a Glance Lisa Ellington 5/6/22 How FDA Is Funded; User Fee Reauthorization Legislation Released in the House; White House Conference on Hunger, Nutrition, and Health Announced for September Read More
Analysis and Commentary Lisa Ellington 5/6/22 Analysis and Commentary Lisa Ellington 5/6/22 Alliance Members Encouraged to Submit Testimony to House Ag/FDA Subcommittee in Support of the Alliance’s FY 23 “Ask” Read More
Analysis and Commentary Lisa Ellington 4/29/22 Analysis and Commentary Lisa Ellington 4/29/22 What Dr. Califf Said to the Senate; What CVM Director Dr. Solomon Said to the Alliance Read More
Advocacy at a Glance Lisa Ellington 4/29/22 Advocacy at a Glance Lisa Ellington 4/29/22 Commissioner Califf Testifies in Senate; House/Senate Appropriations Leaders Have First Informal Chat About Total Spending for FY 23; Inspections, Budgeting, and the Pandemic Read More
Analysis and Commentary STEVEN GROSSMAN 4/22/22 Analysis and Commentary STEVEN GROSSMAN 4/22/22 Q&A: the President’s Budget Request and our Hill visits to advocate for more FDA funding. Read More
Advocacy at a Glance STEVEN GROSSMAN 4/22/22 Advocacy at a Glance STEVEN GROSSMAN 4/22/22 Alliance Concludes Second Round of Hill Visits to Request Increased FDA Funding; Tapes/transcripts for past/upcoming Alliance webinars Read More
Analysis and Commentary STEVEN GROSSMAN 4/15/22 Analysis and Commentary STEVEN GROSSMAN 4/15/22 Summaries of the Alliance webinars with Associate Commissioner for Regulatory Affairs Judy McMeekin and with CFSAN Director Dr. Susan Mayne Read More
Advocacy at a Glance STEVEN GROSSMAN 4/15/22 Advocacy at a Glance STEVEN GROSSMAN 4/15/22 More on President’s request for an FDA BA of $3.653 Billion Total; Volunteers Sought for Hill Meetings April 20/21 and beyond Read More
Advocacy at a Glance STEVEN GROSSMAN 4/8/22 Advocacy at a Glance STEVEN GROSSMAN 4/8/22 Alliance Supports Administration Call for $336 Million Increase in FY 23; Encouraging Members of Congress to request increased FDA funding. Read More
Analysis and Commentary STEVEN GROSSMAN 4/8/22 Analysis and Commentary STEVEN GROSSMAN 4/8/22 Summary of the Alliance webinar with CDER Director Dr. Patrizia Cavazzoni Read More
Analysis and Commentary STEVEN GROSSMAN 4/1/22 Analysis and Commentary STEVEN GROSSMAN 4/1/22 Administration seeks FY23 FDA Increase of $336 Million; New Resources Support Broad Range of FDA Programs. Read More
Advocacy at a Glance STEVEN GROSSMAN 4/1/22 Advocacy at a Glance STEVEN GROSSMAN 4/1/22 President’s FY 23 budget request FAQ’s Read More
